VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin

Cellular Oncology

Volumn 34, Issue 3, 2011, Pages 225-234

  Nyhan, Michelle J ^a   Mashad, Shereen M El ^a   O'Donovan, Tracey R ^a   Ahmad, Sarfraz ^b   Collins, Chris ^a   Sweeney, Paul ^b   Rogers, Eamonn ^b   O'Sullivan, Gerald C ^b   McKenna, Sharon L ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Clear cell renal cell carcinoma (CCRCC); Hypoxia Inducible Factor (HIF); Mutation; Putative targets; Von hippel lindau (VHL)

Indexed keywords

CARBONATE DEHYDRATASE IX; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OSTEOPONTIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; HIF1A PROTEIN, HUMAN; TUMOR ANTIGEN; VHL PROTEIN, HUMAN;

ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MUTATION; OSTEOPONTIN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84555187527     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0029-5     Document Type: Article

References (33)

1. E.C. Nelson, C.P. Evans, P.N. Lara Jr., Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33, 299-313 (2007) (Pubitemid 46767941)
2. W.Y. Kim, W.G. Kaelin, Role of VHL gene mutation in human cancer. J Clin Oncol 22, 4991-5004 (2004) (Pubitemid 46646218)
3. W.G. Kaelin Jr., The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8, 865-873 (2008)
4. E.B. Rankin, A.J. Giaccia, The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15, 678-685 (2008) (Pubitemid 351405072)
5. S.V. Ivanov, I. Kuzmin, M.H. Wei, S. Pack, L. Geil, B.E. Johnson, E.J. Stanbridge, M.I. Lerman, Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-Type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95, 12596-12601 (1998) (Pubitemid 28483810)
6. P.A. Pioli, W.F. Rigby, The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J Biol Chem 276, 40346-40352 (2001)
7. J.M. Purkerson, G.J. Schwartz, The role of carbonic anhydrases in renal physiology. Kidney Int 71, 103-115 (2007) (Pubitemid 46094683)
8. Q.T. Le, P.D. Sutphin, S. Raychaudhuri, S.C. Yu, D.J. Terris, H.S. Lin, B. Lum, H.A. Pinto, A.C. Koong, A.J. Giaccia, Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9, 59-67 (2003) (Pubitemid 36109716)
9. K. Matusan, G. Dordevic, D. Stipic, V. Mozetic, K. Lucin, Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 94, 325-331 (2006) (Pubitemid 44330856)
10. J.D. Gordan, P. Lal, V.R. Dondeti, R. Letrero, K.N. Parekh, C.E. Oquendo, R.A. Greenberg, K.T. Flaherty, W.K. Rathmell, B. Keith, M.C. Simon, K.L. Nathanson, HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446 (2008)
11. X. Na, G. Wu, C.K. Ryan, S.R. Schoen, P.A. di'Santagnese, E.M. Messing, Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170, 588-592 (2003) (Pubitemid 36870265)
12. K.J. Turner, J.W. Moore, A. Jones, C.F. Taylor, D. Cuthbert-Heavens, C. Han, R.D. Leek, K.C. Gatter, P.H. Maxwell, P.J. Ratcliffe, D. Cranston, A.L. Harris, Expression of hypoxiainducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62, 2957-2961 (2002) (Pubitemid 34525785)
13. M.S. Wiesener, P.M. Munchenhagen, I. Berger, N.V. Morgan, J. Roigas, A. Schwiertz, J.S. Jurgensen, G. Gruber, P.H. Maxwell, S. A. Loning, U. Frei, E.R. Maher, H.J. Grone, K.U. Eckardt, Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61, 5215-5222 (2001) (Pubitemid 32681556)
14. O. Iliopoulos, A. Kibel, S. Gray, W.G. Kaelin Jr., Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1, 822-826 (1995)
15. M.W. Pfaffl, A new mathematical model for relative quantification in real-Time RT-PCR. Nucleic Acids Res 29, e45 (2001)
16. M. Garayoa, Y.G. Man, A. Martinez, F. Cuttitta, J.L. Mulshine, Downregulation of hnRNP A2/B1 expression in tumor cells under prolonged hypoxia. Am J Respir Cell Mol Biol 28, 80-85 (2003) (Pubitemid 36017053)
17. A. Verhulst, V.P. Persy, A.R. Van Rompay, W.A. Verstrepen, M.F. Helbert, M.E. De Broe, Osteopontin synthesis and localization along the human nephron. J Am Soc Nephrol 13, 1210-1218 (2002) (Pubitemid 34441401)
18. J.H. Kim, C.W. Jung, Y.H. Cho, J. Lee, S.H. Lee, H.Y. Kim, J. Park, J.O. Park, K. Kim, W.S. Kim, Y.S. Park, Y.H. Im, W.K. Kang, K. Park, Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13, 859-864 (2005)
19. M. Bailly, C. Bain, M.C. Favrot, M. Ozturk, Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. Int J Cancer 63, 660-664 (1995)
20. H. Brauch, G. Weirich, J. Brieger, D. Glavac, H. Rodl, M. Eichinger, M. Feurer, E. Weidt, C. Puranakanitstha, C. Neuhaus, S. Pomer, W. Brenner, P. Schirmacher, S. Storkel, M. Rotter, A. Masera, N. Gugeler, H.J. Decker, VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60, 1942-1948 (2000) (Pubitemid 30207656)
21. S.J. Mandriota, K.J. Turner, D.R. Davies, P.G. Murray, N.V. Morgan, H.M. Sowter, C.C. Wykoff, E.R. Maher, A.L. Harris, P.J. Ratcliffe, P.H. Maxwell, HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002) (Pubitemid 41039126)
22. K. Kondo, W.Y. Kim, M. Lechpammer, W.G. Kaelin Jr., Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1, E83 (2003)
23. M.M. Baldewijns, I.J. van Vlodrop, K.M. Smits, P.B. Vermeulen, G.G. Van den Eynden, F. Schot, T. Roskams, H. van Poppel, M. van Engeland, A.P. de Bruine, Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. Cell Oncol 31, 371-382 (2009)
24. S.C. Clifford, D. Astuti, L. Hooper, P.H. Maxwell, P.J. Ratcliffe, E.R. Maher, The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 20, 5067-5074 (2001) (Pubitemid 32769798)
25. Y. Murakami, K. Kanda, M. Tsuji, H. Kanayama, S. Kagawa, MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. Br J Urol Int 83, 743-747 (1999) (Pubitemid 29224388)
26. J.J. Patard, P. Fergelot, P.I. Karakiewicz, T. Klatte, Q.D. Trinh, N. Rioux-Leclercq, J.W. Said, A.S. Belldegrun, A.J. Pantuck, Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 123, 395-400 (2008) (Pubitemid 351842025)
27. K. Grabmaier, A.d.W. MC, G.W. Verhaegh, J.A. Schalken, E. Oosterwijk, Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23, 5624-5631 (2004) (Pubitemid 39093040)
28. R.R. Raval, K.W. Lau, M.G. Tran, H.M. Sowter, S.J. Mandriota, J.L. Li, C.W. Pugh, P.H. Maxwell, A.L. Harris, P.J. Ratcliffe, Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25, 5675-5686 (2005) (Pubitemid 40853601)
29. C.C. Wykoff, N.J. Beasley, P.H. Watson, K.J. Turner, J. Pastorek, A. Sibtain, G.D. Wilson, H. Turley, K.L. Talks, P.H. Maxwell, C. W. Pugh, P.J. Ratcliffe, A.L. Harris, Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60, 7075-7083 (2000) (Pubitemid 32059187)
30. A. Nishie, K. Masuda, M. Otsubo, T. Migita, M. Tsuneyoshi, K. Kohno, T. Shuin, S. Naito, M. Ono, M. Kuwano, High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res 7, 2145-2151 (2001) (Pubitemid 32994855)
31. M.J. Nyhan, G.C. O'Sullivan, S.L. McKenna, Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 36, 472-478 (2008) (Pubitemid 351839358)
32. P.P. Kapitsinou, V.H. Haase, The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 15, 650-659 (2008) (Pubitemid 351405068)
33. I.J. Frew, C.R. Thoma, S. Georgiev, A. Minola, M. Hitz, M. Montani, H. Moch, W. Krek, pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27, 1747-1757 (2008)